Hamlin Capital Management, LLC Gilead Sciences, Inc. Transaction History

Hamlin Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 13, 2020	SELL	$62.1 - $78.08 $39.3 Million - $49.4 Million	-632,397 Closed	0 $0
Q2 2020 Jul 15, 2020	BUY	$72.34 - $84.0 $7.32 Million - $8.5 Million	101,172 Added 19.05%	632,397 $48.7 Million
Q1 2020 May 11, 2020	SELL	$62.63 - $80.22 $13.9 Million - $17.8 Million	-221,517 Reduced 29.43%	531,225 $39.7 Million
Q4 2019 Jan 17, 2020	BUY	$61.62 - $67.78 $358,751 - $394,615	5,822 Added 0.78%	752,742 $48.9 Million
Q3 2019 Oct 16, 2019	BUY	$62.51 - $69.0 $22.2 Million - $24.5 Million	354,950 Added 90.56%	746,920 $47.3 Million
Q2 2019 Jul 22, 2019	BUY	$61.87 - $69.38 $24.3 Million - $27.2 Million	391,970 New	391,970 $26.5 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Hamlin Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Hamlin Capital Management, LLC with notifications on news.